Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 3
2004 4
2005 2
2006 1
2007 7
2008 9
2009 8
2010 10
2011 10
2012 18
2013 10
2014 18
2015 6
2016 8
2017 7
2018 4
2019 5
2020 4
2021 7
Text availability
Article attribute
Article type
Publication date

Search Results

125 results
Results by year
Filters applied: . Clear all
Page 1
131I-labeled Anti-HER2 Camelid sdAb as a Theranostic Tool in Cancer Treatment.
D'Huyvetter M, De Vos J, Xavier C, Pruszynski M, Sterckx YGJ, Massa S, Raes G, Caveliers V, Zalutsky MR, Lahoutte T, Devoogdt N. D'Huyvetter M, et al. Among authors: lahoutte t. Clin Cancer Res. 2017 Nov 1;23(21):6616-6628. doi: 10.1158/1078-0432.CCR-17-0310. Epub 2017 Jul 27. Clin Cancer Res. 2017. PMID: 28751451 Free PMC article.
Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C, Vanhoeij M, Duhoux FP, Gevaert T, Simon P, Schallier D, Fontaine C, Vaneycken I, Vanhove C, De Greve J, Lamote J, Caveliers V, Lahoutte T. Keyaerts M, et al. Among authors: lahoutte t. J Nucl Med. 2016 Jan;57(1):27-33. doi: 10.2967/jnumed.115.162024. Epub 2015 Oct 8. J Nucl Med. 2016. PMID: 26449837 Free article. Clinical Trial.
Immuno-imaging using nanobodies.
Vaneycken I, D'huyvetter M, Hernot S, De Vos J, Xavier C, Devoogdt N, Caveliers V, Lahoutte T. Vaneycken I, et al. Among authors: lahoutte t. Curr Opin Biotechnol. 2011 Dec;22(6):877-81. doi: 10.1016/j.copbio.2011.06.009. Epub 2011 Jul 2. Curr Opin Biotechnol. 2011. PMID: 21726996 Review.
Bioluminescence imaging: looking beyond the light.
Keyaerts M, Caveliers V, Lahoutte T. Keyaerts M, et al. Among authors: lahoutte t. Trends Mol Med. 2012 Mar;18(3):164-72. doi: 10.1016/j.molmed.2012.01.005. Epub 2012 Feb 8. Trends Mol Med. 2012. PMID: 22321645 Review.
Therapeutic Efficacy of 213Bi-labeled sdAbs in a Preclinical Model of Ovarian Cancer.
Dekempeneer Y, Caveliers V, Ooms M, Maertens D, Gysemans M, Lahoutte T, Xavier C, Lecocq Q, Maes K, Covens P, Miller BW, Bruchertseifer F, Morgenstern A, Cardinaels T, D'Huyvetter M. Dekempeneer Y, et al. Among authors: lahoutte t. Mol Pharm. 2020 Sep 8;17(9):3553-3566. doi: 10.1021/acs.molpharmaceut.0c00580. Epub 2020 Aug 13. Mol Pharm. 2020. PMID: 32787284
Stromal-targeting radioimmunotherapy mitigates the progression of therapy-resistant tumors.
Bolli E, D'Huyvetter M, Murgaski A, Berus D, Stangé G, Clappaert EJ, Arnouk S, Pombo Antunes AR, Krasniqi A, Lahoutte T, Gonçalves A, Vuylsteke M, Raes G, Devoogdt N, Movahedi K, Van Ginderachter JA. Bolli E, et al. Among authors: lahoutte t. J Control Release. 2019 Nov 28;314:1-11. doi: 10.1016/j.jconrel.2019.10.024. Epub 2019 Oct 15. J Control Release. 2019. PMID: 31626860
125 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page